These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 25229990)
21. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial. Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307 [TBL] [Abstract][Full Text] [Related]
22. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Galaal K; Naik R; Bristow RE; Patel A; Bryant A; Dickinson HO Cochrane Database Syst Rev; 2010 Jun; 2010(6):CD007822. PubMed ID: 20556785 [TBL] [Abstract][Full Text] [Related]
23. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Nicholson S; Bomphray CC; Thomas H; McIndoe A; Barton D; Gore M; George AJ Cancer Immunol Immunother; 2004 Sep; 53(9):809-16. PubMed ID: 15127236 [TBL] [Abstract][Full Text] [Related]
24. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis. Mei L; Hou Q; Fang F; Wang H Eur J Gynaecol Oncol; 2016 Aug; 37(4):455-460. PubMed ID: 29894066 [TBL] [Abstract][Full Text] [Related]
25. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Shylasree TS; Bryant A; Athavale R Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006246. PubMed ID: 23450567 [TBL] [Abstract][Full Text] [Related]
26. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. Rodríguez PC; Rodríguez G; González G; Lage A MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330 [TBL] [Abstract][Full Text] [Related]
27. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Falcetta FS; Lawrie TA; Medeiros LR; da Rosa MI; Edelweiss MI; Stein AT; Zelmanowicz A; Moraes AB; Zanini RR; Rosa DD Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005344. PubMed ID: 27737492 [TBL] [Abstract][Full Text] [Related]
28. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale. Everest L; Shah M; Chan KKW JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990 [TBL] [Abstract][Full Text] [Related]
29. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Grisham RN; Berek J; Pfisterer J; Sabbatini P Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756 [TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Dobrzanski MJ; Lockwood-Cooke PR; Robinson W J Immunother; 2012; 35(2):196-204. PubMed ID: 22306908 [TBL] [Abstract][Full Text] [Related]
31. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551 [No Abstract] [Full Text] [Related]
32. Nutritional Interventions to Improve Clinical Outcomes in Ovarian Cancer: A Systematic Review of Randomized Controlled Trials. Rinninella E; Fagotti A; Cintoni M; Raoul P; Scaletta G; Quagliozzi L; Miggiano GAD; Scambia G; Gasbarrini A; Mele MC Nutrients; 2019 Jun; 11(6):. PubMed ID: 31234395 [TBL] [Abstract][Full Text] [Related]
33. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. Khalili N; Keshavarz-Fathi M; Shahkarami S; Hirbod-Mobarakeh A; Rezaei N J Oncol Pharm Pract; 2019 Jun; 25(4):903-917. PubMed ID: 30348069 [TBL] [Abstract][Full Text] [Related]
34. How can molecular abnormalities influence our clinical approach. Wei W; Giulia F; Luffer S; Kumar R; Wu B; Tavallai M; Bekele RT; Birrer MJ Ann Oncol; 2017 Nov; 28(suppl_8):viii16-viii24. PubMed ID: 29232470 [TBL] [Abstract][Full Text] [Related]
35. Targeted immune therapy of ovarian cancer. Knutson KL; Karyampudi L; Lamichhane P; Preston C Cancer Metastasis Rev; 2015 Mar; 34(1):53-74. PubMed ID: 25544369 [TBL] [Abstract][Full Text] [Related]
36. A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy. Peper JK; Stevanović S Cancer Immunol Immunother; 2015 Oct; 64(10):1295-303. PubMed ID: 25822767 [TBL] [Abstract][Full Text] [Related]
37. Immunity and immune suppression in human ovarian cancer. Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194 [TBL] [Abstract][Full Text] [Related]
38. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. Leary AF; Quinn M; Fujiwara K; Coleman RL; Kohn E; Sugiyama T; Glasspool R; Ray-Coquard I; Colombo N; Bacon M; Zeimet A; Westermann A; Gomez-Garcia E; Provencher D; Welch S; Small W; Millan D; Okamoto A; Stuart G; Ochiai K; Ann Oncol; 2017 Apr; 28(4):718-726. PubMed ID: 27993794 [TBL] [Abstract][Full Text] [Related]
39. Physical activity and exercise in women with ovarian cancer: A systematic review. Jones TL; Sandler CX; Spence RR; Hayes SC Gynecol Oncol; 2020 Sep; 158(3):803-811. PubMed ID: 32616402 [TBL] [Abstract][Full Text] [Related]
40. Research waste among randomized controlled trials in ovarian cancer: A cross-sectional study. Lin L; Tang Y; Yang L; Wang Y; Chen R Eur J Surg Oncol; 2024 Jul; 50(7):108437. PubMed ID: 38820926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]